Literature DB >> 8413708

[Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis].

D A Breems1, P W de Haas, F Visscher, L J Sabbe, H F Busch, P A van Doorn.   

Abstract

Dermatomyositis is an acquired disease characterised by symmetric predominantly proximal muscle weakness of the arms and legs, and misery. It may be associated with myalgia and there is often a characteristic rash. The mainstay of therapy is corticosteroids. Recently efficacy of intravenous immunoglobulin (IVIg) in chronic refractory dermatomyositis was reported. Because corticosteroids can cause serious side effects, we treated a seven-year-old girl suffering from dermatomyositis with IVIg as initial therapy. After two courses of IVIg infusions at a dose of 0.4 g/kg/day for five consecutive days, the patient made a rapid and complete recovery. This case shows that IVIg may be effective as initial therapy in patients with dermatomyositis. Whether IVIg is really a better treatment than corticosteroids should be investigated in a randomised study.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8413708

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  3 in total

1.  From black magic to science: understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies.

Authors:  S Y Patel; D S Kumararatne
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

Review 2.  [Intravenous immunoglobulins in chronic idiopathic myositis].

Authors:  H Michels; G-R Burmester; F Buttgereit
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

3.  Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids.

Authors:  Deborah M Levy; C April Bingham; Philip J Kahn; Andrew H Eichenfield; Lisa F Imundo
Journal:  J Pediatr       Date:  2009-10-28       Impact factor: 4.406

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.